Agios Pharmaceuticals, Inc. (8AP.F)
| Previous Close | 29.00 |
| Open | 29.40 |
| Bid | 29.00 x 20000 |
| Ask | 29.60 x 20000 |
| Day's Range | 29.40 - 29.40 |
| 52 Week Range | 18.80 - 31.80 |
| Volume | |
| Avg. Volume | 9 |
| Market Cap | 1.652B |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.90 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 62.43 |
ZacksAnalysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GlobeNewswireAgios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
CAMBRIDGE, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 2, 2024, at 8:00 a.m. ET to report its first quarter 2024 financial results and other business highlights. A live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the co
GuruFocus.comDirector Jacqualyn Fouse Sells Shares of Agios Pharmaceuticals Inc (AGIO)
Agios Pharmaceuticals Inc (NASDAQ:AGIO), a biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of cancer and rare genetic diseases, has seen a recent insider transaction according to the latest SEC filings.
